207 related articles for article (PubMed ID: 23318765)
21. Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol.
Guo M; Zhao Q; Fan S; Wu Z; Lin L; Chen H; Gao Y; Hai X
Br J Clin Pharmacol; 2021 Oct; 87(10):4020-4026. PubMed ID: 33638869
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
[No Abstract] [Full Text] [Related]
23. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Shen ZX; Chen GQ; Ni JH; Li XS; Xiong SM; Qiu QY; Zhu J; Tang W; Sun GL; Yang KQ; Chen Y; Zhou L; Fang ZW; Wang YT; Ma J; Zhang P; Zhang TD; Chen SJ; Chen Z; Wang ZY
Blood; 1997 May; 89(9):3354-60. PubMed ID: 9129042
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Fox E; Razzouk BI; Widemann BC; Xiao S; O'Brien M; Goodspeed W; Reaman GH; Blaney SM; Murgo AJ; Balis FM; Adamson PC
Blood; 2008 Jan; 111(2):566-73. PubMed ID: 17959855
[TBL] [Abstract][Full Text] [Related]
25. Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3.
Šlejkovec Z; Podgornik H; Černelč P; Falnoga I
Biometals; 2016 Feb; 29(1):107-18. PubMed ID: 26671504
[TBL] [Abstract][Full Text] [Related]
26. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
27. Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang H; Xi S; Liu Z; Yang Y; Zheng Q; Wang F; Xu Y; Wang Y; Zheng Y; Sun G
Environ Toxicol; 2013 May; 28(5):267-75. PubMed ID: 23589229
[TBL] [Abstract][Full Text] [Related]
28. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
29. Biotransformation of arsenic and toxicological implication of arsenic metabolites.
Hirano S
Arch Toxicol; 2020 Aug; 94(8):2587-2601. PubMed ID: 32435915
[TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
31. Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.
Talbot S; Nelson R; Self WT
Br J Pharmacol; 2008 Jul; 154(5):940-8. PubMed ID: 18587442
[TBL] [Abstract][Full Text] [Related]
32. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
Westervelt P; Brown RA; Adkins DR; Khoury H; Curtin P; Hurd D; Luger SM; Ma MK; Ley TJ; DiPersio JF
Blood; 2001 Jul; 98(2):266-71. PubMed ID: 11435292
[TBL] [Abstract][Full Text] [Related]
33. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
Lin CJ; Wu MH; Hsueh YM; Sun SS; Cheng AL
Cancer Chemother Pharmacol; 2005 Feb; 55(2):170-8. PubMed ID: 15322825
[TBL] [Abstract][Full Text] [Related]
34. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
Leung J; Pang A; Yuen WH; Kwong YL; Tse EW
Blood; 2007 Jan; 109(2):740-6. PubMed ID: 16968895
[TBL] [Abstract][Full Text] [Related]
35. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
[No Abstract] [Full Text] [Related]
36. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
Kiguchi T; Yoshino Y; Yuan B; Yoshizawa S; Kitahara T; Akahane D; Gotoh M; Kaise T; Toyoda H; Ohyashiki K
Leuk Res; 2010 Mar; 34(3):403-5. PubMed ID: 19733394
[TBL] [Abstract][Full Text] [Related]
37. Arsenic: an old enemy now turned friend.
Firkin F; Iland H
Leuk Lymphoma; 2013 Sep; 54(9):1864-6. PubMed ID: 23550992
[No Abstract] [Full Text] [Related]
38. Biomethylation metabolism study of arsenite in SCC-7 cells by reversed phase ion pair high performance liquid chromatography-inductively coupled plasma-mass spectrometry.
Li Y; Chen B; He M; Hu B
Talanta; 2018 Oct; 188():210-217. PubMed ID: 30029366
[TBL] [Abstract][Full Text] [Related]
39. Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients.
Wu M; Pang C; Lu S; Hostetter TH; Hai X
Environ Toxicol Pharmacol; 2023 Jun; 100():104142. PubMed ID: 37146668
[TBL] [Abstract][Full Text] [Related]
40. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Chou WC; Dang CV
Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
